ITGAV and breast carcinoma: These data support the hypothesis that decreased overall integrin expression indicates increased cilengitide sensitivity and suggest that, in addition to utility in a subset of TNBC patients, cilengitide, or other ITGAV inhibitors, may be effective in luminal breast cancers as a whole.